Jonathan Zalevsky Sells 1,157 Shares of Nektar Therapeutics (NASDAQ:NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) insider Jonathan Zalevsky sold 1,157 shares of the stock in a transaction on Tuesday, November 25th. The shares were sold at an average price of $54.28, for a total value of $62,801.96. Following the completion of the transaction, the insider owned 18,971 shares of the company’s stock, valued at $1,029,745.88. The trade was a 5.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Jonathan Zalevsky also recently made the following trade(s):

• On Thursday, September 4th, Jonathan Zalevsky sold 1,721 shares of Nektar Therapeutics stock. The shares were sold at an average price of $33.52, for a total value of $57,687.92.
• On Tuesday, September 2nd, Jonathan Zalevsky sold 485 shares of Nektar Therapeutics stock. The stock was sold at an average price of $30.10, for a total value of $14,598.50.

Nektar Therapeutics Stock Up 8.8%

Shares of NKTR opened at $65.69 on Thursday. The stock has a market cap of $1.34 billion, a PE ratio of -7.47 and a beta of 1.19. Nektar Therapeutics has a 12-month low of $6.45 and a 12-month high of $66.92. The business has a 50-day simple moving average of $58.60 and a two-hundred day simple moving average of $35.14.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings results on Thursday, November 6th. The biopharmaceutical company reported ($1.85) earnings per share for the quarter, topping the consensus estimate of ($2.85) by $1.00. Nektar Therapeutics had a negative return on equity of 631.43% and a negative net margin of 163.17%.The company had revenue of $11.79 million for the quarter, compared to analysts’ expectations of $10.20 million. On average, equities research analysts expect that Nektar Therapeutics will post -0.72 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on NKTR. Jefferies Financial Group reissued a “buy” rating and set a $121.00 target price (up from $99.00) on shares of Nektar Therapeutics in a report on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Nektar Therapeutics in a report on Tuesday. Citigroup assumed coverage on Nektar Therapeutics in a report on Wednesday. They issued a “buy” rating and a $102.00 price objective for the company. B. Riley raised their target price on Nektar Therapeutics from $85.00 to $105.00 and gave the stock a “buy” rating in a research report on Tuesday, September 23rd. Finally, Wall Street Zen lowered Nektar Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, November 16th. Six research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Nektar Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $106.33.

Institutional Investors Weigh In On Nektar Therapeutics

A number of institutional investors have recently modified their holdings of the company. BNP Paribas Financial Markets increased its position in shares of Nektar Therapeutics by 93.8% during the third quarter. BNP Paribas Financial Markets now owns 434 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 210 shares during the period. FNY Investment Advisers LLC bought a new stake in Nektar Therapeutics during the second quarter valued at $39,000. Compass Wealth Management LLC acquired a new stake in Nektar Therapeutics during the 3rd quarter worth about $88,000. Bessemer Group Inc. grew its holdings in Nektar Therapeutics by 1,741.2% during the 3rd quarter. Bessemer Group Inc. now owns 1,565 shares of the biopharmaceutical company’s stock worth $90,000 after acquiring an additional 1,480 shares during the period. Finally, Bayforest Capital Ltd bought a new position in shares of Nektar Therapeutics in the 3rd quarter worth about $96,000. 75.88% of the stock is owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.